Drug Combo Proves Powerful Against Lung Cancer Babylon NY

A two-drug combination treatment in Babylon proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Shirley Mathew, MD
516-872-2200
2 Oak Ln
Roslyn Heights, NY
J Raychaudhuri, MD
Cold Spring Harbor, NY
Rana Zoeb, MD
74 Southaven Ave Ste C
Medford, NY
Jeffrey Gary Schneider, MD
516-663-9500
4 Dianas Cir
Roslyn, NY
Mamta T Choks, MD
516-663-9500
Ste 450 200 OldCountry Rd
Mineola, NY
Alexander Hindenburg
(516) 663-4608
200 Old Country Rd
Mineola, NY
Vijaykumar Ratanlal Shah, MD
2201 Hempstead Tpke
East Meadow, NY
Jeffrey Lee Vacirca, MD
631-751-3000
235 North Belle Rd
East Setauket, NY
Moshe Weiner, MD
516-546-5000
2209 Merrick Rd
Merrick, NY
Romeo D Balagot, MD
516-731-0124
4277 Hempstead Tpke Ste 107
Bethpage, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Genetic Clues for Skin Cancer Therapies Babylon NY
Scientists have isolated a group of genetic mutations involved in the growth of melanoma, the deadliest form of skin cancer. Their work may lead to therapies with existing drugs that target the same mutations. Led by Yardena Samuels of the National Human Genome Research Institute, the research team from the U.S. National Institutes of Health (NIH) sequenced the protein tyrosine kinase (PTK) gene family in tumor and blood samples from people with metastatic melanoma.
- Fungal Infection Treatments Babylon NY
- Side Effect Of Chemotherapy Drugs Babylon NY
- Exercise for Breast Cancer Survival Babylon NY
- Delayed Prostate Cancer Therapy Babylon NY
- Exercise for Prostate Cancer Babylon NY
- Hormone Therapy for Lung Cancer Babylon NY
- Hormone Therapy for Breast Cancer Babylon NY
- Risks for Childhood Cancer Survivors Babylon NY